Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection.
Mangia A, Minerva N, Bacca D, Cozzolongo R, Agostinacchio E, Sogari F, Scotto G, Vinelli F, Ricci GL, Romano M, Carretta V, Petruzzellis D, Andriulli A. Mangia A, et al. Among authors: cozzolongo r. Hepatology. 2009 Feb;49(2):358-63. doi: 10.1002/hep.22679. Hepatology. 2009. PMID: 19072829
Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver.
Gramenzi A, Conti F, Cammà C, Grieco A, Picciotto A, Furlan C, Romagno D, Costa P, Rendina M, Ancarani F, Chiaramonte M, Verucchi G, Craxì A, Bernardi M, Andreone P; AISF HepaElder Study Group. Gramenzi A, et al. Dig Liver Dis. 2012 Aug;44(8):674-80. doi: 10.1016/j.dld.2012.03.009. Epub 2012 Apr 25. Dig Liver Dis. 2012. PMID: 22538206
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.
Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, Boninsegna S, Farci P, Fargion S, Giuberti T, Iannacone C, Regep L, Massetto B, Facchetti F, Colombo M; PegBeLiver Study Group. Lampertico P, et al. Gut. 2013 Feb;62(2):290-8. doi: 10.1136/gutjnl-2011-301430. Epub 2012 Aug 2. Gut. 2013. PMID: 22859496 Clinical Trial.
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin.
Andriulli A, Di Marco V, Margaglione M, Ippolito AM, Fattovich G, Smedile A, Valvano MR, Calvaruso V, Gioffreda D, Milella M, Morisco F, Felder M, Brancaccio G, Fasano M, Gatti P, Tundo P, Barone M, Cozzolongo R, Angelico M, D'Andrea G, Andriulli N, Abate ML, Mazzella G, Gaeta GB, Craxi A, Santantonio T. Andriulli A, et al. Among authors: cozzolongo r. J Hepatol. 2014 Jan;60(1):16-21. doi: 10.1016/j.jhep.2013.07.040. Epub 2013 Aug 20. J Hepatol. 2014. PMID: 23973930 Free article.
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.
Andriulli A, Nardi A, Di Marco V, Ippolito AM, Gavrila C, Aghemo A, Di Paolo D, Squadrito G, Grassi E, Calvaruso V, Valvano MR, Brancaccio G, Craxi A, Angelico M; Collaborators. Andriulli A, et al. Dig Liver Dis. 2014 Sep;46(9):818-25. doi: 10.1016/j.dld.2014.05.015. Epub 2014 Jun 20. Dig Liver Dis. 2014. PMID: 24953209
81 results